Showing 901-910 of 2874 results for "".
Headache Medicine Update: What’s New in CGRP Functional Blocking Agents
https://practicalneurology.com/diseases-diagnoses/headache-pain/headache-medicine-update-whats-new-in-cgrp-functional-blocking-agents/32126/CGRP blocking agents have demonstrated success in migraine treatment and can be used in various settings, in different combinations, and for different headache conditions.Neurologic Manifestations & Associations of COVID-19
https://practicalneurology.com/diseases-diagnoses/imaging-testing/neurologic-manifestations-associations-of-covid-19/31739/High-quality epidemiologic data is still urgently needed to better understand neurologic effects of COVID-19.Diagnostic Considerations for New-Onset Epilepsy in Older Adults
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/diagnostic-considerations-for-new-onset-epilepsy-in-older-adults/32175/Early recognition and accurate diagnosis by health care providers are key to the optimal management of the older adult with epilepsy.Occipital Neuralgia & Cervicogenic Headache
https://practicalneurology.com/diseases-diagnoses/headache-pain/occipital-neuralgia-cervicogenic-headache/31787/Occipital neuralgia and cervicogenic headache have similar anatomy and treatment.Rational Polypharmacy for Migraine
https://practicalneurology.com/diseases-diagnoses/headache-pain/rational-polypharmacy-for-migraine/31898/Polypharmacy can be effective for migraine refractory to monotherapy.Neuromuscular Notes: Exercise and Rehabilitation Medicine in Neuromuscular Disease
https://practicalneurology.com/diseases-diagnoses/neuromuscular/neuromuscular-notes-exercise-and-rehabilitation-medicine-in-neuromuscular-disease/32094/Exercise and rehabilitative interventions for individuals with neuromuscular disorders require careful design and multidisciplinary management.Tuberous Sclerosis Complex
https://practicalneurology.com/diseases-diagnoses/child-neurology/tuberous-sclerosis-complex/31942/Tuberous sclerosis complex represents the opportunity of targeted treatment resulting from identifying pathogenic gene variants for long-recognized syndromes.Discontinuing Disease-Modifying Therapies in Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/discontinuing-disease-modifying-therapies-in-multiple-sclerosis/31875/Over the course of multiple sclerosis, there may come a point where the risks of disease-modifying therapies outweigh the benefits.Rise of the Genomic Medicine Era in Amyotrophic Lateral Sclerosis
https://practicalneurology.com/diseases-diagnoses/neuromuscular/rise-of-the-genomic-medicine-era-in-amyotrophic-lateral-sclerosis/32024/Advances in gene-targeted therapies are positioned to transform clinical treatment for familial and sporadic amyotrophic lateral sclerosis.MS Minute: Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease/32180/MOGAD, an inflammatory demyelinating disease of the central nervous system, has some overlapping clinical features with NMOSD and MS but is a distinct entity with unique pathologic, clinical, and imaging features.